<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Medicinova Inc — News on 6ix</title>
<link>https://6ix.com/company/medicinova-inc</link>
<description>Latest news and press releases for Medicinova Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 23:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/medicinova-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359bf478dffbe2df106f52.webp</url>
<title>Medicinova Inc</title>
<link>https://6ix.com/company/medicinova-inc</link>
</image>
<item>
<title>New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation</title>
<link>https://6ix.com/company/medicinova-inc/news/new-peerreviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/new-peerreviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation</guid>
<pubDate>Mon, 27 Apr 2026 23:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastas</description>
</item>
<item>
<title>MediciNova to Participate at the 38th Annual ROTH Conference</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-to-participate-at-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-to-participate-at-the-38th-annual-roth-conference</guid>
<pubDate>Mon, 16 Mar 2026 11:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer will participate at the 38th Annual ROTH Conference. The conference is being held on March 22 – 24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Poin</description>
</item>
<item>
<title>MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-announces-100-patients-enrolled-230000005</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-announces-100-patients-enrolled-230000005</guid>
<pubDate>Thu, 29 Jan 2026 23:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-en</description>
</item>
<item>
<title>2026 New Year’s Greetings from the CEO</title>
<link>https://6ix.com/company/medicinova-inc/news/2026-greetings-ceo-140000012</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/2026-greetings-ceo-140000012</guid>
<pubDate>Tue, 06 Jan 2026 14:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. Dear Fellow Shareholders, The year 2025 was marked by global uncertainty, with accelerating inflation, evolving U.S. trade policies under the new administration, and</description>
</item>
<item>
<title>MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-announces-completion-patient-enrollment-110000742</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-announces-completion-patient-enrollment-110000742</guid>
<pubDate>Thu, 18 Dec 2025 11:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led</description>
</item>
<item>
<title>MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-announces-basic-characteristic-randomized-110000782</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-announces-basic-characteristic-randomized-110000782</guid>
<pubDate>Mon, 08 Dec 2025 11:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND, held Decem</description>
</item>
<item>
<title>Message from the CEO to MediciNova Shareholders</title>
<link>https://6ix.com/company/medicinova-inc/news/message-ceo-medicinova-shareholders-230000283</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/message-ceo-medicinova-shareholders-230000283</guid>
<pubDate>Mon, 01 Dec 2025 23:00:00 GMT</pubDate>
<description>Strengthening MN-001’s Scientific Foundation and Clinical OutlookLA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provide additional perspective on why this research represents a significant milestone for MediciNova and our MN-001 program. The study, conducted in collaboration with a leading Japanese academic research team, revealed a novel mechanism by MN-002, the prim</description>
</item>
<item>
<title>MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-appoints-dr-christopher-breder-110000830</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-appoints-dr-christopher-breder-110000830</guid>
<pubDate>Tue, 18 Nov 2025 11:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova’s Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D</description>
</item>
<item>
<title>MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-wins-contract-research-development-230000669</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-wins-contract-research-development-230000669</guid>
<pubDate>Thu, 06 Nov 2025 23:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that the company has been selected as a winner of the “Contract Research and Development Innovation Award” at the Fifth Annual BioTech Breakthrough Awards. MediciNova earned this recognition for its innovative work advancing MN-166 (ibudilast), the company’s lead small</description>
</item>
<item>
<title>MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-announces-completion-patient-enrollment-120000978</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-announces-completion-patient-enrollment-120000978</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completion of patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (Tipelukast) for the treatment of hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM). Patient recruitment is closed</description>
</item>
<item>
<title>MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-compounds-demonstrate-novel-therapeutic-230000370</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-compounds-demonstrate-novel-therapeutic-230000370</guid>
<pubDate>Thu, 30 Oct 2025 23:00:00 GMT</pubDate>
<description>Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patientsLA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces the publication of a new research article in the peer-reviewed Journal of Atherosclerosis and T</description>
</item>
<item>
<title>MediciNova to Present at the LD Micro Main Event XIX Investor Conference</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-present-ld-micro-main-120000807</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-present-ld-micro-main-120000807</guid>
<pubDate>Mon, 06 Oct 2025 12:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will present a corporate overview at the LD Micro Main Event XIX Investor Conference. The conference is being held on October 19 – 22, 2025 at the Hote</description>
</item>
<item>
<title>MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-announces-completion-patient-enrollment-120000066</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-announces-completion-patient-enrollment-120000066</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>~Patient Recruitment Closed~LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 patients have been randomized across tw</description>
</item>
<item>
<title>MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-announces-poster-presentation-combat-120000364</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-announces-poster-presentation-combat-120000364</guid>
<pubDate>Tue, 16 Sep 2025 12:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients has been selected for a poster presentation at 36th International Symposium on ALS/MND to be held December 5-7, 2025 in San Diego</description>
</item>
<item>
<title>MediciNova Provides Shareholder Update on Key Developments</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-provides-shareholder-key-developments-130000037</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-provides-shareholder-key-developments-130000037</guid>
<pubDate>Mon, 08 Sep 2025 13:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), provides a shareholder update recapping important developments for the Company. Standby Equity Purchase Agreement (SEPA) The Company reported the signing of a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of</description>
</item>
<item>
<title>MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-present-h-c-wainwright-110000251</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-present-h-c-wainwright-110000251</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, MD., Ph.D., President and CEO, and David H. Crean, PhD, Chief Business Officer will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 a</description>
</item>
<item>
<title>MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-achieves-enrollment-combat-als-230000141</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-achieves-enrollment-combat-als-230000141</guid>
<pubDate>Tue, 26 Aug 2025 23:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it successfully achieved enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast). MN-166 is currently in development for the treatment of Amyotrophic Lateral Sclerosis (ALS). Dr. Yuichi Iwaki, MediciNova Pr</description>
</item>
<item>
<title>MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-announces-signing-standby-equity-233000764</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-announces-signing-standby-equity-233000764</guid>
<pubDate>Thu, 31 Jul 2025 23:30:00 GMT</pubDate>
<description>LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months. Under the Agreement, the Company shall have the right, but not the obligation, to sell its common stock in individual transactions – or</description>
</item>
<item>
<title>MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-provides-enrollment-ongoing-als-100000709</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-provides-enrollment-ongoing-als-100000709</guid>
<pubDate>Thu, 24 Jul 2025 10:00:00 GMT</pubDate>
<description>MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patientsLA JOLLA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides an update on the enrollment of two key ongoing clinical trials for the Company’s developm</description>
</item>
<item>
<title>MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025</title>
<link>https://6ix.com/company/medicinova-inc/news/medicinova-participate-d-boral-capital-230000823</link>
<guid isPermaLink="true">https://6ix.com/company/medicinova-inc/news/medicinova-participate-d-boral-capital-230000823</guid>
<pubDate>Mon, 14 Apr 2025 23:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital’s, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and p</description>
</item>
</channel>
</rss>